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AIM AND BACKGROUND 
The European Society of Cardiology criteria suggests anticoagulant treatment in non-valvular 
atrial fibrillation in most cases.  
The proportion of patients with anticoagulant treatment was high.  
Anticoagulant therapy is the most effective treatment in non-valvular atrial fibrillation for prevention of thromboembolism. The purpose of 
the study is to evaluate the appropriateness of anticoagulant therapy in non-valvular atrial fibrillation in the general population of a 
primary care based on criteria of European Society of Cardiology. 
DESIGN AND METHODS 
Design: Descriptive, cross-sectional study was carried out in an urban primary health care center in Barcelona, Spain.  
Patients and Methods: Patients with non-valvular atrial fibrillation of the center were studied (electronic database). The variables 
analyzed included demographic data, treatment (anticoagulant or antiplatelet therapy), and criteria for anticoagulant therapy.  
RESULTS 
 
CONCLUSIONS 
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ACO  
Therapy 
YES 124 (66,3) 7 (87,5%) 
NO 63 (33,7%) 1 (12,5%) 
 93,8% of patients had CHA2DS2-VASc ≥ ≥ 2 points 
 In this case, 77,1% were taking anticoagulants and 19.2% antiplatelet therapy. 
 6,7% of the remaining patients had a CHA2DS2-VASc <2 points, 43,8% were 
taking anticoagulant therapy and 31,6% taking antiplatelet therapy.  
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ACO  
Therapy 
YES 185 (77,1%) 7 (43,8%) 
NO 55 (22,9%) 9 (56,3%) 
 Only 4,1% of patients had a HAS-BLED ≥ 3 points 
 In this case, 87,5% were taking anticoagulants and 12,5% antiplatelet therapy. 
 95,9% of the remaining patients had a HAS-BLED < 3 points, 66,3% were 
taking anticoagulant therapy and 26,7% antiplatelet therapy. 
 CRITERIA FOR ANTICOAGULANT THERAPY 
 CHA2DS2-VASc: anticoagulant therapy indicated if ≥ 2 points 
 1 point: 
 Congestive heart failure/Left ventricular dysfunction 
 Hypertension (HTA) 
 Diabetes mellitus (DM) 
 Peripheral vascular disease 
 Myocardial infarction 
 Age 65-74 years 
 Female sex 
 2 points: 
 Age ≥ 75 years 
 Stroke/TIA/thromboembolism 
CRITERIA TO CONTRAINDICATE ANTICOAGULANT THERAPY  
HAS-BLED: risk of bleeding if ≥ 3 points 
 All scored 1 point: 
 Systolic blood pressure >160 mmHg 
 Stroke 
 Labile INR (<60% remain in the therapeutic time range) 
 Age >65 years 
 Abnormal renal function 
 Abnormal liver function 
 Alcohol abuse 
 Taking other drugs that may increase the bleeding risk 
 
 
256 patients had a diagnosi of non-valvular atrial fibrillation. 
The mean age was 78,6 years ( SD 9,1 ). 
56,6% of patients were women. 
HTA 80,1%. 
Hypercholesterolemia 33,2%. 
DM 28,5%. 
Smoking people 7% ( ex-smoking people 21,1% ). 
Drugs for rhythm control 75,4%. 
 
